… the pathophysiology of COVID-19 coagulopathy in the … in the past year of antithrombotic
therapy in patients who are … on optimal use of antithrombotic therapy in patients with COVID-19. …

… of the pattern of COVID-19 not only in epidemiology and immunology but also in subsequent
coagulopathy and coagulopathy treatment strategies. COVID-19 is associated with a …

… , risk of venous thromboembolism (VTE), or antithrombotic therapy for patients infected with
… In summary, the coagulopathy associated with SARS-CoV-2 infection typically presents with …

… COVID-19 severity and mortality. We aim to review the available data on the coagulopathy
observed in COVID-19 … : Implications for prevention, antithrombotic therapy, and follow-up. J …

… in COVID-19 cases. Current evidence suggests COVID-19 associated coagulopathy is a …
The presence of coagulopathy as part of the systemic inflammatory response syndrome is a …

… among 150 patients with Covid-19 and acute respiratory … with Covid-19 and those with
non-Covid-19 infection-associated … In patients with non-Covid-19 infection-associated ARDS, 2.1…

… immunomodulatory agents. In the pre-COVID-19 era, the reason we gave antithrombotics in
… In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day …

… risk of contracting or developing severe COVD-19 due to taking antithrombotic agents.Patients
receiving antiplatelet or anticoagulant therapies for underlying conditions should continue …

… COVID-19–associated coagulopathy should be managed as it would be for any critically ill
patient, … with resultant disruption of the natural antithrombotic state is likely. An early report of …

… COVID-19 in Germany, antiplatelet monotherapy (mostly acetylsalicylic acid) showed no
benefit. The patients treated with antiplatelet agents … indicated that antiplatelet treatment could …